Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs APX 005M (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 19 Apr 2017 Planned End Date changed from 1 May 2020 to 1 Jun 2020.
- 19 Apr 2017 Planned primary completion date changed from 1 May 2020 to 1 Jun 2020.